American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 391-394 , September 2008

Statins for Slowing Kidney Disease Progression: An as yet Unproven Indication

  • Marcello Tonelli, MD, SM, FRCPC

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marcello Tonelli, MD, SM, FRCPC, Department of Medicine, University of Alberta, 7-129 Clinical Sciences Building, 8440-112 St, Edmonton, Alberta T6G 2G3, Canada

References 

  1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  2. ALLHAT Officers and Coordinators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  3. Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412–424
  4. Pasternak RC. The ALLHAT lipid lowering trial—less is less. JAMA. 2002;288:3042–3044
  5. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145:520–530
  6. Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  7. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651
  8. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  9. Tonelli M. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  10. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–1139
  11. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1134
  12. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1453
  13. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13:2898–2908
  14. Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 2002;61:1635–1644
  15. Liao J. Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. Am J Cardiol. 2005;96:24–33
  16. Mario Negri Institute for Pharmacological Research. Statins in Proteinuric Nephropathies. http://clinicaltrials.gov/ct2/show/NCT00199927?term=esplanade&rank=12008;Accessed July 8
  17. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;S207–S210
  18. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563

 No paper or electronic reprints will be available.

PII: S0272-6386(08)01106-2

doi: 10.1053/j.ajkd.2008.07.010

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 391-394 , September 2008

Article Tools